Literature DB >> 36061578

Differences in the Composition of Activated Partial Thromboplastin Time (APTT) Reagents Affect Clot Waveform Analysis.

Konami Kato1, Yuki Hatayama1, Hisashi Shimohiro2, Hitomi Ichikawa1, Tetsuya Fukuda1.   

Abstract

Background: Clot waveform analysis (CWA) based on activated partial thromboplastin time (APTT) is a useful assay for hemostasis. However, the effects of activators and phospholipid conditions on CWA have not been adequately investigated. Therefore, we characterized CWA using four different APTT reagents.
Methods: We used 39 archived plasma samples from patients with hemophilia A (HA), 16 samples from patients with HA under emicizumab treatment, and 10 samples from healthy individuals for CWA with four different types of APTT reagents (reagents A, B, C, and D). We then compared Ad|min1|, Ad|min2|, and Ad|max2| from the CWA, which reflect the maximum velocity, maximum acceleration, and maximum deceleration, respectively, among the four reagents.
Results: Similar clot waveform shapes were observed for each reagent in the healthy donor group, HA group, and HA under emicizumab group, and the waveform was different for each target group. Significant changes were found in clotting time (CT) (s), Ad|min1| (%/s), Ad|min2| (%/s2), and Ad|max2| (%/s2). The waveform pattern for the coagulation reaction by reagent D, comprising silica and synthetic phospholipids, was the fastest among the reagents examined. Further, the difference in Ad|min1| (%/s) and Ad|min2| (%/s2) was larger than that in CT depending on the reagent used(s), indicating that the measured value of CWA was affected by the reagent composition.
Conclusion: Our results showed a significant difference among reagents with varying composition and concentration; this was found to affect the parameters obtained from CWA. Thus, the differences between reagents hinder standardization of quantitative evaluation using these parameters; further, this highlights the necessity of understanding the characteristics of APTT reagents and determining the reference range in individual facilities. ©2022 Tottori University Medical Press.

Entities:  

Keywords:  activated partial thromboplastin time; clot waveform; emicizumab; hemophilia A

Year:  2022        PMID: 36061578      PMCID: PMC9419218          DOI: 10.33160/yam.2022.08.013

Source DB:  PubMed          Journal:  Yonago Acta Med        ISSN: 0513-5710            Impact factor:   1.371


  18 in total

1.  A study of atypical APTT derivative curves on the ACL TOP coagulation analyser.

Authors:  C Solano; P Zerafa; R Bird
Journal:  Int J Lab Hematol       Date:  2011-02       Impact factor: 2.877

Review 2.  Towards standardization of clot waveform analysis and recommendations for its clinical applications.

Authors:  M Shima; J Thachil; S C Nair; A Srivastava
Journal:  J Thromb Haemost       Date:  2013-07       Impact factor: 5.824

Review 3.  Clot waveform analysis: Where do we stand in 2017?

Authors:  P O Sevenet; F Depasse
Journal:  Int J Lab Hematol       Date:  2017-09-06       Impact factor: 2.877

Review 4.  Waveform analysis of clotting test optical profiles in the diagnosis and management of disseminated intravascular coagulation (DIC).

Authors:  C H Toh; A R Giles
Journal:  Clin Lab Haematol       Date:  2002-12

5.  Investigation of the freely available easy-to-use software 'EZR' for medical statistics.

Authors:  Y Kanda
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

Review 6.  A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis.

Authors:  Marcus D Lancé
Journal:  Thromb J       Date:  2015-01-12

7.  Clot waveform of APTT has abnormal patterns in subjects with COVID-19.

Authors:  Takuya Shimura; Makoto Kurano; Yoshiaki Kanno; Mahoko Ikeda; Koh Okamoto; Daisuke Jubishi; Sohei Harada; Shu Okugawa; Kyoji Moriya; Yutaka Yatomi
Journal:  Sci Rep       Date:  2021-03-04       Impact factor: 4.379

8.  Regression Analysis to Estimate the Factor VIII Activity of Patients with Hemophilia A Without Inhibitor who Received Emicizumab Therapy.

Authors:  Yuki Hatayama; Toru Motokura; Yuzuru Hosoda; Sayaka Suzuki; Hiroya Namba; Konami Kato; Nao Kojima; Takuya Horie; Takuya Iwamoto; Noriko Yamashita; Hitomi Ichikawa; Tetsuya Fukuda
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

9.  Assessment of aPTT-based clot waveform analysis for the detection of haemostatic changes in different types of infections.

Authors:  Chuen Wen Tan; Wan Hui Wong; McVin Hua Heng Cheen; Yvonne Miao Hui Chu; Shan Shan Lim; Lawrence Cheng Kiat Ng; Dillon Guo Dong Yeo; Gayathry Morvil; Lai Heng Lee; Heng Joo Ng
Journal:  Sci Rep       Date:  2020-08-25       Impact factor: 4.379

Review 10.  Laboratory testing in hemophilia: Impact of factor and non-factor replacement therapy on coagulation assays.

Authors:  Flora Peyvandi; Gili Kenet; Isabell Pekrul; Rajiv K Pruthi; Peter Ramge; Michael Spannagl
Journal:  J Thromb Haemost       Date:  2020-04-23       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.